A share price of ProQR Therapeutics N.V [PRQR] is currently trading at $2.42, up 6.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PRQR shares have gain 7.56% over the last week, with a monthly amount glided 5.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ProQR Therapeutics N.V [NASDAQ: PRQR] stock has seen the most recent analyst activity on January 10, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $15. Previously, Raymond James upgraded its rating to Strong Buy on October 29, 2024, and elevated its price target to $14. On November 08, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $2 on the stock. JMP Securities upgraded its rating to a Mkt Outperform and increased its price target to $5 on March 30, 2023. Cantor Fitzgerald upgraded its rating to a Overweight and raised its price target to $5 on December 22, 2022. Citigroup downgraded its rating to Neutral for this stock on February 14, 2022, and downed its price target to $1.70. In a note dated February 11, 2022, Stifel downgraded an Hold rating on this stock and revised its target price from $20 to $3.
ProQR Therapeutics N.V experienced fluctuations in its stock price throughout the past year between $1.61 and $4.62. Currently, Wall Street analysts expect the stock to reach $3.63 within the next 12 months. ProQR Therapeutics N.V [NASDAQ: PRQR] shares were valued at $2.42 at the most recent close of the market. An investor can expect a potential return of 50.0% based on the average PRQR price forecast.
Analyzing the PRQR fundamentals
Trailing Twelve Months sales for ProQR Therapeutics N.V [NASDAQ:PRQR] were 19.37M which represents 183.27% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -1.67%, Pretax Profit Margin comes in at -1.35%, and Net Profit Margin reading is -1.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.71 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.31 points at the first support level, and at 2.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.49, and for the 2nd resistance point, it is at 2.55.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ProQR Therapeutics N.V [NASDAQ:PRQR] is 2.33. Also, the Quick Ratio is 2.33, while the Cash Ratio stands at 2.26. Considering the valuation of this stock, the price to sales ratio is 12.89, the price to book ratio is 7.09.
